The startup specializes in the production of hyaluronic acid dermal fillers utilizing a unique crosslinking mechanism that preserves the integrity of natural hyaluronic acid chains. This technology enables effective non-invasive aesthetic treatments for visible wrinkles and facial reshaping, providing clients with a more natural appearance.
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current hyaluronic acid (HA) dermal fillers often utilize crosslinking methods that can damage the HA polymer chains, leading to reduced elasticity and a less natural look and feel. Many consumers are concerned about unnatural results, potential side effects like swelling and lumps, and the short duration of existing HA fillers.
Solution
Hallura provides a line of HA dermal fillers that utilize a proprietary BiOLinkMatrix technology, inspired by the 2022 Nobel Prize in Chemistry, to crosslink HA with minimal modification to the native HA polymer. This innovative approach preserves the long HA chains, resulting in a gel with pure elasticity that closely mimics the properties of youthful skin. Hallura's fillers are BDDE-free and designed to stimulate the production of collagen I, III, and elastin, promoting skin rejuvenation and natural-looking results. Clinical trials have demonstrated excellent efficacy, a strong safety profile, and long-lasting results, with many subjects reporting minimal swelling and a natural feel after injection. The Hallura product line includes formulations for lip enhancement, wrinkle smoothing, and facial volume restoration.
Target Audience
Hallura's primary customers are healthcare professionals in the aesthetic medicine field, including dermatologists, plastic surgeons, and cosmetic injectors, seeking high-quality, safe, and effective dermal fillers for their patients.
Features
- BiOLinkMatrix technology: A novel crosslinking method that preserves the integrity of long HA chains for enhanced elasticity.
- BDDE-free formulation: Reduces the risk of adverse reactions and ensures high purity.
- Bio-stimulation: Stimulates the production of collagen I, III, and elastin for skin rejuvenation.
- Long-lasting results: Clinical studies demonstrate effectiveness over 18 months.
- Natural look and feel: Gels integrate seamlessly with the body's own tissue for a natural appearance.
- Low concentration options: Available in varying HA concentrations (4 mg/mL, 6 mg/mL, 8 mg/mL) for tailored treatments and reduced swelling.
- Excellent safety profile: Clinical trials show minimal post-injection side effects.
- Three product variations: HLR-1 for lips, HLR-2 for wrinkles, and HLR-3 for facial remodeling.